The p53 gene is a tumor suppressor that regulates the expression of genes required for cell cycle arrest or apoptosis. Mutations in p53 have been observed in over 60% of all human cancers. Certain classes of mutant p53 proteins maintain some of their activities or acquire novel activities and thus may contribute to the transformed phenotype. By carrying out an analysis of dierential gene expression using cDNA expression arrays, we compared the expression patterns of cells expressing no p53 to isogenic lines expressing the codon 248 Arg to Trp mutant p53 allele (R248W). In this report, we show that the R248W and D281G p53 mutants, two of the more commonly occurring mutations, as well as wild type p53, repress transcription of the tissue inhibitor of metalloproteinases type 3 (TIMP-3) gene by greater than tenfold. TIMP-3 expression has been observed to be repressed in many tumors and its reduced expression is thought to contribute to tumor metastasis and invasiveness by allowing increased activity of metalloproteinases in the extracellular matrix. Since mutant forms of p53 tend to be expressed at greatly elevated levels in many human tumors, the retention of their ability to repress TIMP-3 illustrate one mechanism by which mutant forms of the p53 gene may contribute to tumorigenesis.
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The tumor suppressor p53 protein mediates cell cycle arrest or apoptosis in part by directly modulating mRNA transcription. In normal cells, the level of p53 protein, which is very low, is induced as well as activated in response to DNA damage, cell stress such as hypoxia (Giaccia and Kastan, 1998; Levine et al., 1994; Prives, 1998; Schwartz and Rotter, 1998) or the expression of oncogenes through the recently described ARF pathway (Bates et al., 1998; Sherr, 1998) . Activated p53 binds to its consensus DNA binding site Funk et al., 1992) and functions as a transcription factor thereby aecting the expression of a number of downstream genes. Transcriptional activation by p53 occurs through its amino terminal domain which has been shown to interact with a number of general transcription factors such as TFIIH (Xiao et al., 1994) , the TATA-binding protein (TBP) (Farmer et al., 1996a; Horikoshi et al., 1995) , TBP-associated factors TAF II 31 and TAF II 40 (Lu and Thut et al., 1995) , and the transcriptional coactivator p300/CBP (Avantaggiati et al., 1997; Gu et al., 1997; Lill et al., 1997) . A number of potential p53 responsive genes have been identi®ed which include, among others, MDM2 (Barak et al., 1993) , WAF1/CIP1/p21 , GADD45 (Kastan et al., 1992) , Bax (Miyashita and Reed, 1995) , cyclin G (Okamoto and Beach, 1994 ), 14-3-3s (Hermeking et al., 1997) , and c-fos (Elkeles et al., 1999) . These genes all contain a consensus wild type p53 recognition sequence.
Wild type p53 can also repress the expression of downstream genes. It has been demonstrated that wild type p53 can interact with the TATA box-binding protein, TBP, or other components of the transcription initiation complex and repress RNA polymerase II transcription of both RNA polymerase II and III transcribed genes (Cairns and White, 1998; Farmer et al., 1996b; Mack et al., 1993; Ragimov et al., 1993; Seto et al., 1992; Yew et al., 1994) . These include cellular promoters such as c-jun, hsp70, DNA topoisomerase II a, MAP4, alpha-fetoprotein, parathyroid hormone-related protein (PTHrP), a subset of ribosomal protein genes, and viral promoters such as the SV40, Rous sarcoma virus and hepatitis B virus promoters (Ago et al., 1993; Budde and Grummt, 1999; Foley et al., 1996; Ginsberg et al., 1991; Jackson et al., 1993; Lee et al., 1999; Murphy et al., 1996; Subler et al., 1992; Wang et al., 1997) .
Mutations that inactivate the cell cycle arrest or apoptotic activities of p53 have been identi®ed in over 60% of all human tumors assayed. Relative to other tumor suppressor genes which exhibit mutations that lead to loss of gene function, the vast majority of mutations in p53 are missense mutations that encode full-length proteins with amino acid substitutions (Hussain and Harris, 1998; Levine, 1997; Levine et al., 1994) . Furthermore, mutant p53 is expressed as elevated levels in transformed cells due to both transcriptional and post-transcriptional mechanisms (Balint and Reisman, 1996; Giaccia and Kastan, 1998; Prives, 1998) . This has lead to the hypothesis that mutations in p53 can result concomitantly in the loss of tumor suppressor activities and the acquisition of oncogenic activities (Hussain and Harris, 1998; Levine et al., 1994) . Consistent with this hypothesis, mutant p53 expression in a number of dierent p53-null cell types has been demonstrated to enhance their growth rates and tumorigenicities, as well as their potential for increased tissue invasiveness (Chen et al., 1990; Gerwin et al., 1992; Hsiao et al., 1994; Shaulsky et al., 1991; Shohat et al., 1987; Sun et al., 1993) . A gain-of-function for mutant p53 protein is supported by demonstrations that a subset of tumor derived mutant p53 genes can modulate the expression of a number of cellular and viral promoters including the human MDR1, EGFR, PTHrP, and c-myc promoters and the HIV Type I LTR (Chin et al., 1992; Deb et al., 1992; Foley et al., 1996; Frazier et al., 1998; Gualberto et al., 1995; Ludes-Meyers et al., 1996) as well as bind speci®cally to DNA elements of the nuclear matrix (Muller et al., 1996; or disrupt spindle formation checkpoints (Gualberto et al., 1998) . These ®ndings indicate that some oncogenic p53 proteins carrying missense mutations may contribute to the transformed phenotype by aberrantly altering the expression of genes that participate in growth regulation. Supporting the idea that transcriptional regulation by mutant p53 is required for its transforming activity, Lin et al. (1995) demonstrated that mutations in the amino terminal transactivation domain of p53 destroy both the transforming and gene regulatory activities of mutant p53. In order to increase our understanding of the contribution of mutant p53 to the transformed phenotype, we have searched for genes whose expression is altered in response to mutant p53 expression.
To identify genes that are regulated by mutant p53, we carried out an analysis of dierential gene expression in cells expressing a tumor-derived mutant p53 compared to p53-null cells. The human colon carcinoma derived R248W p53 mutant (codon 248 Arg to Trp) was placed under the control of either the cytomegalovirus (CMV) promoter or the glucocorticoid inducible mouse mammary tumor virus (MMTV) LTR and these constructs were stably introduced into the p53-null murine cell line 10(3). The 10(3) cell line lacks endogenous p53 expression due to a point mutation causing a premature translation stop codon and which results in rapid degradation of the mutant message (Harvey and Levine, 1991) . These cells are well suited for these experiments because while they are immortalized, they do not exhibit a transformed phenotype. They are contact inhibited, do not form colonies in soft-agar, and do not form tumors in syngeneic or athymic nude mice. However, they can be transformed into tumorigenic cells by the introduction of the codon 248 mutant p53 (Dittmer et al., 1993) . The introduction of the CMV ± 248p53 and the MMTV ± 248p53 into these cells therefore allowed for the constitutive and inducible expression, respectively, of mutant p53 in an otherwise p53-null background. As shown in Figure 1a , cells carrying the CMV ± 248p53 were observed to express levels of mutant p53 comparable to that found in the human Burkitt's lymphoma line Raji. Cells carrying the MMTV ± 248p53 ( Figure 1b ) were observed to express extremely low or undetectable levels of mutant p53 in the absence (CMV) promoter. This plasmid also expresses the E. coli neomycin phosphotransferase gene. After approximately two weeks under selection (G418 600 mg/ml), clones were expanded into cell lines. To generate cell lines that would express inducible mutant p53, the pMSG (Pharmacia) mammalian expression vector carrying the p53 mutant (Arg to Trp at codon 248) cDNA was transfected into the 10(3) cells. This plasmid also expresses the E. coli xanthineguanine phosphoribosyltransferase gene. After approximately two weeks under selection [mycophenolic acid (15 mg/ml), xanthine (250 mg/ml), hypoxanthine (15 mg/ml), aminopterine (2 mg/ml) and thymidine (10 mg/ml)], clones were expanded into cell lines. Induction of expression of the MMTV promoter was carried out by addition of 5 mM dexamethasone to the culture media. Cell extracts were prepared and Western blots were performed to assay for mutant p53 expression. Membranes were incubated with antip53 monoclonal antibodies pAb421 and DO-1 for 1 h followed by washing and subsequent incubation with horseradish peroxidase (HRP)-conjugated sheep anti-mouse antibody. Proteins were visualized by chemiluminescence (Amersham) and exposed to X-ray ®lm from 15 s to 1 h. Cell extracts were assayed from parental 10(3) cells and from cells carrying the construct expressing the codon R248W mutant p53 from the CMV promoter, designated CMV248.2, CMV248.6, and CMV248.9 (A) and from cells carrying the construct expressing the R248W mutant p53 from the dexamethasone inducible MMTV LTR, designated MMTV26, 31 and 32 (B and (C). The Burkitt's lymphoma cell line, Raji, was used as a positive control. (B) 10(3)-derived cells (MMTV26, 31 and 32) carrying the dexamethasone inducible MMTV based construct were treated with 5 mM dexamethasone for 18 h prior to harvesting for protein. Western transfer was carried out to assay for p53 protein in cells either untreated (7) or treated with dexamethasone (+). (C) Clone MMTV26 was assayed for the induction of p53 protein levels as a function of time after treatment with 5 mM dexamethasone of dexamethasone and high levels of mutant p53 as early as 2 h after treatment with dexamethasone. Maximal levels of mutant p53 were achieved by 12 ± 16 h after induction (Figure 1c) .
In order to carry out an analysis of genes dierentially expressed in these cells, poly(A) + RNA was isolated from the parental 10(3) cells, from cells constitutively expressing the codon 248 mutant (clone CMV248.2), and from cells expressing the inducible codon 248 mutant (clone MMTV32) at eighteen hours after treatment with dexamethasone. 32 P-labeled cDNA was prepared from each RNA sample and used as hybridization probes onto three ®lters each carrying an array of 588 known murine cDNAs. The dierences in the intensities of hybridization signals obtained when comparing between the dierent samples allows the Figure 2 Analysis of dierential gene expression in p53-null and mutant p53 expressing cells. Mouse Atlas cDNA Expression Arrays (Clontech) were prehybridized in 50% formamide, 66SSC, 0.1% SDS, 1 mM EDTA, 26Denhardt's, and 100 mg/ml sheared single stranded DNA at 428C for 24 h. One microgram each of poly(A) + mRNA from the 10(3), CM248.2 and MMTV32 cell lines were reverse transcribed in the presence [a-32 P]-dCTP to synthesize labeled cDNA. The cDNA was puri®ed by CHROMA SPIN-200 column chromatography (Clontech). Fractions were collected and counted by liquid scintillation. The peak fractions were pooled and denatured. 2610 7 c.p.m. of the respective probes were added to each blot and hybridization was carried out in 50% formamide, 66SSC, 0.1% SDS, 1 mM EDTA, 26 Denhardt's solution, and 100 mg/ml sheared single stranded DNA at 428C for 72 h. Following multiple washings at 428C with 16SSPE (150 mM NaCl, 10 mM NaH 2 PO 4 and 1 mM EDTA), and 0.1% SDS, signals were detected using a Storm 860 phosphoimager (Molecular Dynamics) as well as autoradiography. The ®lters were stripped and reprobed to verify results. (A) 32 P-labeled cDNA was prepared from poly(A) + RNA isolated from 10(3) and CMV248.2 cells. Each labeled cDNA population was hybridized to an individual cDNA array. Results are shown for that location of the array harboring the cDNA found to have reduced expression in the presence of mutant p53 (noted by arrows). This location was found to contain the cDNA for TIMP-3. The levels of hybridization to a series of controls are also shown. These arrays were carried out in duplicate. (B) Northern transfer analysis showing reduced expression TIMP-3 in the presence of mutant p53. Total RNA was isolated from 10(3) and from CMV248.2 cells as well as from MMTV26 before and 18 h after treatment with 5 mM dexamethasone. 10 mg of each were separated by agarose gel electrophoresis, transferred to nitrocellulose and hybridized to 32 P-labeled TIMP-3 cDNA. The ®lters were stripped and rehybridized with 32 P-labeled b-actin cDNA as an internal control. The hybridization signals were detected by autoradiography. Shown are examples of the results obtained in two independent assays identi®cation of genes that are dierentially expressed among the dierent cell types. Examples of results of these assays are shown in Figure 2A . While controls such as b-actin, GAPDH and ubiquitin as well as the majority of the cDNAs assayed exhibited approximately equal hybridization signals when comparing the p53-null and R248W p53 expressing cells, one position in the array consistently revealed a gene that appeared to be expressed at signi®cantly lower levels in the cells expressing the p53 mutant protein (indicated by arrows in Figure 2A ). Similar results were obtained when the cDNA arrays were probed with labeled cDNA from the cells expressing inducible mutant p53. The gene was identi®ed as the tissue inhibitor of metalloproteinases-3 (TIMP-3; GenBank accession #L19622). The TIMP-3 gene encodes a protein that is associated with the extracellular matrix (ECM) and which has been shown to inhibit the activity of matrix metalloproteinases (Anand-Apte et al., 1996; Gomez et al., 1997; Woessner, 1991) . The TIMP-2 gene, also present on the array was expressed at extremely low levels in both p53-null and p53-mutant cell types. Interestingly, the loss of TIMP-3 expression has been observed in a number of human cancers and transformed cells (Anand-Apte et al., 1996; Andreu et al., 1998; Chan et al., 1998) . Since the matrix metalloproteinases participate in degrading basement membranes and the ECM, the increased activity of these proteinases due to the loss of inhibitors such as TIMP-3 has been proposed to play a critical role in tumor metastasis (Anand-Apte et al., 1996; Chan et al., 1998; Gomez et al., 1997; Sato et al., 1994; Ueno et al., 1997; Vassalli and Pepper, 1994; Yu and Stamenkovic, 1999) . Since TIMP-3 expression has been postulated to inhibit tumor invasion and metastasis, the ability of the R248W p53 allele to repress TIMP-3 expression could have major signi®cance with respect to cancer progression.
To con®rm that the level of TIMP-3 expression is reduced in the presence of mutant p53, we assayed for the level of TIMP-3 mRNA in the parental p53-null 10(3) cells and in the cell lines expressing the constitutive and inducible mutant p53 genes. As shown in Figure 2B , the level of the TIMP-3 mRNA is reduced approximately sixfold, as measured by phosphoimaging, in cells expressing mutant p53. Since it has been demonstrated previously that TIMP-3 expression is induced upon treatment of cells with dexamethasone (Leco et al., 1994) , the reduction of TIMP-3 expression observed here upon induction of mutant p53 expression by dexamethasone, as well as by the observation that TIMP-3 expression is reduced in cells constitutively expressing mutant p53, indicates that reduced TIMP-3 is due to the presence of mutant p53 protein in these cells and is not a result of clonal variation among cell lines. These ®ndings indicate that TIMP-3 gene expression is repressed in the presence of mutant p53.
As described above, the wild type p53 protein has been shown to repress transcription of a number of cellular and viral promoters. In order to test whether the murine TIMP-3 promoter may be repressed by mutant p53, we carried out a series of co-transfection assays in 10(3) cells in which we introduced a constant amount of a TIMP-3 luciferase reporter vector, p6AP ( Figure 3A ; Kin et al., 1997; Sun et al., 1995) and increasing amounts of the codon 248 mutant p53 expression vector, pCMV-248p53. Shown in Figure 3 , there was a dose dependent mutant p53-mediated repression of the murine TIMP-3 promoter. At the maximal amount of pCMV-248p53 tested (1 mg), nearly a tenfold reduction in activity was observed. A control plasmid, the pCMV vector, had no eect on the TIMP-3 promoter and was used as a carrier in all Figure 3 (A) Map of the TIMP-3 promoter illustrating the presence of numerous potential regulatory sites as described by Colburn and colleagues (Sun et al., 1995) . (B) Repression of the TIMP-3 promoter by mutant p53. TIMP-3 reporter assays were conducted using the Luciferase Assay System (Promega). Cells were plated at 30% con¯uence one day prior to transfection in 24 well plates. All assays were performed in duplicate. Transfections were carried out by Transfast lipid transfection (Promega) and 48 h after transfection cells were harvested in 100 ml of lysis buer and luciferase assays using equivalent amounts of protein were carried out following standard protocols. Luciferase activity was measured using a Zylux FB12 Manual Luminometer. CAT assays to measure the SV40 CAT internal control or Renilla luciferase assays to measure a HSV TK promoter internal control were carried out using equivalent amounts. Acetylated 14 C-chloramphenicol was assayed via thin-layer chromatography. Signals were detected using a Storm 860 phosphoimager (Molecular Dynamics), as well as autoradiography. 0.5 mg of the TIMP-3/ Luciferase reporter vector was transfected into 10(3) cells in the presence of increasing amounts of the R248W mutant p53 expression vector while reducing the amount of the empty pCMV expression vector (1 mg total DNA). The data are expressed as relative light units and were normalized to the level of expression of either the SV40/CAT reporter or TK/luciferase internal control (50 ng DNA). The experiment was carried out three times in duplicate. (c) Results of co-transfection assays showing repression of the TIMP-3 promoter by both the R248W and D281G mutant p53 alleles. The data from duplicate experiments are expressed as relative repression of the TIMP-3 promoter in response to increasing amounts of eector DNA. All experiments were normalized to the TK promoter internal control transfection experiments. Another commonly occurring mutant p53 allele, carrying the asp to gly substitution and codon 281 (D281G) and expressed from the CMV promoter, was also able to repress the TIMP-3 promoter ( Figure 3C ). Furthermore, there was no eect of mutant p53 on the SV40 early promoter or the HSV TK promoter which were used as internal controls in all transfections (data not shown).
In order to test whether the eect of mutant p53 on the TIMP-3 promoter was speci®c to mutant forms of p53 or whether wild type p53 can also repress TIMP-3 expression, we carried out an analogous series of transfection assays in which we introduced a constant amount of the TIMP-3 luciferase reporter vector and increasing amounts of either the codon 248 mutant p53 expression vector, pCMV-248p53 or the wild type p53 expression vector, pC53-SN 3 . Interestingly, wild type p53 was also able to repress the TIMP-3 promoter and appeared to do so to a slightly greater extent that mutant p53 (Figure 4 ). These ®ndings were observed not only in the p53-null murine line 10(3), but also in NIH3T3 and in two human cell lines, T98G (p53 mutation met to ile at codon 237; Van Meir et al., 1994) and U2OS (wild type p53). Based on our ®ndings that the levels of TIMP-3 mRNA are reduced in the presence of mutant p53 in both the cDNA array hybridization assays and Northern transfer experiments, and that the TIMP-3 promoter is repressed in a dose responsive manner by mutant and by wild type p53, we conclude that p53, either as mutant forms (R248W and D281G), or as wild type, can repress transcription of the TIMP-3 gene.
The cloned TIMP-3 promoter region that was assayed consists of 2.9 Kbp of DNA (Sun et al., 1995) . Previous work has identi®ed a number of transcription factor binding sites within the TIMP-3 promoter ( Figure 3A ) among which includes a suggested wild type p53 consensus binding site at position 7648 to 7620 Sun et al., 1995) . Although this putative p53 binding site has high homology to the consensus site, it was shown previously not to bind to wild type p53 . In view of the presence of this potential p53 binding site in the TIMP-3 promoter, we tested whether R248W mutant p53 protein might be capable of binding to this site. Nuclear extracts were prepared from 10(3) and CMV248.2 cells and tested for the presence of mutant p53 DNA binding activity by electrophoretic mobility shift assays. At the present time, we have no evidence for direct binding by either mutant or wild type p53 to this site (data not shown) and conclude therefore that if p53 interacts directly with the TIMP-3 promoter, it does not do so through the apparent p53 consensus site in the promoter.
As with other promoters that have been demonstrated to be repressed by p53, repression of TIMP-3 may be occurring through interactions of p53 with the TATA box-binding protein, TBP, or other components of the transcription initiation complex (Cairns and White, 1998; Farmer et al., 1996b; Mack et al., 1993; Ragimov et al., 1993; Seto et al., 1992; Yew et al., 1994) . In that wild type p53 represses transcription through interactions with essential components of the transcription initiation complex, direct binding by either mutant or wild type p53 to the promoter may therefore not be required for TIMP-3 repression. Since both the codon 248 and 281 p53 mutants alter residues that make contacts with the DNA target, the tertiary structure is predicted to remain for the most part unaltered (Cho et al., 1994) and to contain a functional amino terminal transcriptional regulatory domain which allow it to interact with factors such as Figure 4 Repression of the TIMP-3 promoter by mutant and wild type p53 in dierent cell types. Cells were plated at 30% con¯uence one day prior to transfection. 0.5 mg of the TIMP-3/Luciferase reporter vector was transfected into the cells indicated in the presence of increasing amounts of either the R248W mutant p53 expression vector or the wild type p53 expression vector while reducing the amount of empty pCMV expression vector (1 mg total DNA). The data are expressed as relative light units (RLU) and were normalized to the level of expression of the TK/luciferase internal control (50 ng DNA). All experiments were performed in duplicate TFIIH, p300/CBP, TBP and additional TAFs. A detailed analysis of the 2.9 Kbp TIMP-3 promoter and identi®cation of a p53-responsive element or elements will allow us to begin to determine the mechanism by which both wild type and oncogenic p53 mutants participate in transcriptional regulation of TIMP-3.
The data that we have presented indicate that both wild type and tumor derived p53 mutants can repress the expression of TIMP-3, a gene thought to play a critical role in turnover and construction of the extracellular matrix and the reduced expression of which has been proposed to contribute to tumor invasion and metastasis (Anand-Apte et al., 1996; Andreu et al., 1998; Brooks et al., 1996; Chan et al., 1998; Gomez et al., 1997; Sato et al., 1994; Ueno et al., 1997; Vassalli and Pepper, 1994; Werb, 1997; Woessner, 1991; Yu and Stamenkovic, 1999) . On the basis of the high frequency of missense mutations seen in human tumors and their expression at elevated levels, it has been proposed for some time that a number of tumor-derived p53 mutants may exhibit oncogenic activity (Dittmer et al., 1993; Hussain and Harris, 1998; Levine et al., 1994) . A number of p53 mutants have in fact been demonstrated to promote growth and enhance the tumorigenic and metastatic potential of cells lacking endogenous p53 (Chen et al., 1990; Gerwin et al., 1992; Hsiao et al., 1994; Shaulsky et al., 1991; Shohat et al., 1987; Sun et al., 1993) . The recent demonstrations that mutant p53 can interfere with a p53-independent apoptotic pathway, inhibit mitotic spindle formation checkpoints and inhibit the activity of the p53 homolog, p73, are likely to contribute to its transforming potential (Blandino et al., 1999; Di Como et al., 1999; Gualberto et al., 1998; Li et al., 1998) . Furthermore, some tumor derived p53 mutants have been demonstrated to dierentially maintain cell cycle arrest functions while exhibiting defects in apoptotic functions (Rowan et al., 1996; Ryan and Vousden, 1998) . The ®nding that both wild type and mutant p53 can repress TIMP-3 transcription, demonstrates that some p53 mutants can apparently retain speci®c wild type activities. The mechanism of repression of TIMP-3 transcription by p53 is now being investigated.
TIMP-3 is one of four known tissue inhibitors of matrix metalloproteinases (MMPs) and is unique among them in its being secreted into the extracellular matrix (Anand-Apte et al., 1996) . The MMPs consist of a family of zinc-requiring proteases. These proteases play a major role in the remodeling and turnover of the extracellular matrix as well as in angiogenesis and in the vascularization of tissues (BenEzra, 1997; Hiraoka et al., 1998; Woessner, 1991) . The aberrant activity of MMPs, leading to a pathological degradation of the extracellular matrix, often appears to be an essential step in cancer progression and metastasis. The degradation of the extracellular matrix is necessary for tumor invasion and accordingly, the activities of MMPs have in some cases been shown to be crucial for this process. Accordingly, MMPs have been found on the surface of, or associated with, a number of invasive and metastatic tumor cell types (Brooks et al., 1996; Sato et al., 1994; Vassalli and Pepper, 1994; Werb, 1997) .
Furthermore, the inhibition of MMP localization to the cell surface inhibits tumor invasiveness (Yu and Stamenkovic, 1999) .
The TIMPs are eective inhibitors of the MMPs and thereby play an important role in regulating MMP activity. As a result, the loss of expression of TIMPs has been linked to states characterized by increased degradation of the extracellular matrix and tumor invasiveness (Anand-Apte et al., 1996; Gomez et al., 1997; Woessner, 1991) . In particular, the loss of expression of TIMP-3 in some cell types has been shown to occur during tumor progression, invasion and metastasis and number of studies have demonstrated a lack of TIMP-3 expression in human colorectal carcinomas, melanomas and invasive breast carcinomas (Andreu et al., 1998; Chan et al., 1998) . In addition, by screening a series of cell lines representing the pre-neoplastic-toneoplastic progression of murine epidermal cells, Colburn and colleagues identi®ed TIMP-3 as a gene whose expression is repressed during tumor progression (Sun et al., 1994) . Furthermore, a number of studies have shown that when introduced into cells and overexpressed, TIMP-3 suppresses tumor growth in vivo and induces apoptosis (Ahonen et al., 1998; Baker et al., 1998; . These results indicate that loss of TIMP-3 expression can participate in tumor progression. In addition to its ability to inhibit extracellular metalloproteases and impede angiogenesis, tumor cell invasion and metastasis, TIMP-3 probably plays a more complex role in cell cycle regulation and the induction of apoptosis. This activity may in part be due to the stabilization of apoptosis-inducing receptors, such as the receptor for TNF-a, on the cell surface by protecting them from MMP activity and resulting in increased sensitization to the induction of apoptosis (Smith et al., 1997) . In view of these ®ndings, TIMP-3 expression is proposed to play a role in tumor suppression and the loss of its expression contributes to the malignant phenotype.
The maintenance of the ability to inhibit TIMP-3 expression by some tumor derived mutant forms of p53 therefore provides a model for understanding how p53 mutations might contribute to tumor progression. In order to become invasive and metastasize, transformed cells must be able to move through the basal lamina and extracellular matrix (ECM). Although wild type p53 appears to repress TIMP-3 expression, since it is generally expressed at very low levels, the eect on TIMP-3 expression would be expected to be minimal. This would explain the high levels of TIMP-3 promoter activity in U2OS cells which express wild type p53 and the repression of TIMP-3 upon overexpression of p53 by transfection of a wild type p53 expression vector (Figure 4 ). Since mutant p53 is stabilized and accumulates to elevated levels in tumor cells, the generation of cells in a non-invasive tumor mass carrying a mutation in p53 would, in addition to losing crucial wild-type p53 mediated cell cycle checkpoints, cause reduced expression of TIMP-3. A similar phenomena, that is repression of the PTHrP gene by both mutant and wild type p53 has been observed in human squamous carcinoma cells (Foley et al., 1996) . In the present case, reduced TIMP-3 expression by overexpressed mutant p53 would result in elevated activity of MMPs and consequently to the increased degradation of the extracellular matrix and basal lamina. Interestingly, in some cancers, such as colorectal cancer where p53 is found to be mutated and overexpressed in over 85% of cases and in which the R248W p53 allele is the most commonly occurring of the p53 mutations, mutations in p53 have been shown to be relatively late events in tumor cell evolution and to be associated with increased metastatic potential (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 1998) . Mutant p53 alleles then, such as R248W or D281G, as a result of their elevated levels, may directly contribute to tumor progression by altering the expression of genes such as TIMP-3.
Note added in proof Multiple mechanisms are likely to contribute to reduced TIMP-3 expression in transformed cells. Pennie et al. (1999) have recently shown that hypermethylation of the TIMP-3 promoter appears to lead to repression of TIMP-3 expression in neoplastic murine JB6 cells.
